Efficacy News and Research

RSS

Age of patients makes a difference in comparing endarteroctomy with carotid stenting for stroke-prevention

A published report provides the final details on how two stroke-prevention procedures are safe and equally beneficial for men and women at risk for stroke, though their effectiveness does vary by age, say researchers at the University of Alabama at Birmingham (UAB) School of Public Health in collaboration with other North American stroke investigators.

28 May 2010

Relevare Pharmaceuticals to present CNSB015 Phase IIa results at international neuropathic pain congress

Relevare Pharmaceuticals Ltd. will present its recent Phase IIa proof-of-concept clinical trial data and extension study results for CNSB015 (flupirtine), its lead repositioned compound, at the Third International Congress on Neuropathic Pain on May 27 –30 in Athens, Greece.

28 May 2010

Effective infant vaccination against pneumonia needed in sub-Saharan Africa

Researchers at the University of Warwick, and the Kenya Medical Research Institute, Kilifi, Kenya, have found that respiratory syncytial virus (RSV) appears to be the predominant virus detected among infants and children hospitalized in Kenya with severe pneumonia, according to a study in the May 26 issue of JAMA. The contribution to this severe disease by an individual pathogen stresses the need for effective infant vaccination.

28 May 2010

Nymox Pharmaceutical announces symposium and panel discussion on NX-1207 drug for BPH

Nymox Pharmaceutical Corporation is pleased to announce the presenters and participants for the symposium and panel discussion on NX-1207, the Company's Phase 3 drug for benign prostatic hyperplasia (BPH), to be held during the 2010 Annual Meeting of the American Urological Association in San Francisco at 3:00 p.m. June 1.

28 May 2010

CytRx's bafetinib demonstrates significant inhibition of glioblastoma multiforme cell lines in preclinical trial

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that its drug candidate bafetinib (formerly known as INNO-406) demonstrated statistically significant inhibition of glioblastoma multiforme cell lines in a preclinical trial. Glioblastoma multiforme is the most common and aggressive primary adult brain tumor.

28 May 2010

Biomedical engineering professor receives Transition Career Development Award

Biomedical engineering professor David Zaharoff has been awarded a Transition Career Development Award by the National Cancer Institute to further his research on Interleukin-12, a powerful cytokine that shows great promise for therapeutic treatment of numerous types of cancer.

28 May 2010

Alimera Sciences provides new data from Iluvien Phase 3 FAME clinical trials for DME

Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that a new analysis of data from its Phase 3 (FAME) clinical trials for Iluvien, the company's investigational intravitreal insert being studied for diabetic macular edema (DME), indicates that patient vision continues to improve significantly over 30 months.

28 May 2010

PAS announces Cross Marketing agreement with MedLink

Patient Access Solutions, Inc., an emerging provider of healthcare/financial processing technologies for the healthcare and home care industry, today announced a Cross Marketing agreement with MedLink, a leading healthcare IT provider of Electronic Health Record, practice management, and clinical integration software to the medical community.

28 May 2010

OHSU partners with UO, Harvard to expedite research into compounds that may prevent Fanconi anemia

Oregon Health & Science University is partnering with the University of Oregon and Harvard Medical School to expedite basic science research into new and existing drugs and compounds that may prevent the complications associated with Fanconi anemia, an inherited condition that can lead to bone marrow failure and cancer.

28 May 2010

Research finding may offer future alternative to antibiotics

A team of scientists from government, academia and private industry has developed a novel treatment that protects mice from infection with the bacterium that causes tularemia, a highly infectious disease of rodents, sometimes transmitted to people, and also known as rabbit fever. In additional experiments with human immune cells, the treatment also demonstrated protection against three other types of disease-causing bacteria that, like the tularemia bacteria, occur naturally, can be highly virulent, and are considered possible agents of bioterrorism.

28 May 2010

CSL Behring granted authorization to market Berinert for HAE in Italy and Luxembourg

CSL Behring announced today it has been granted national marketing authorization in Italy and Luxembourg to market Berinert® for the treatment of acute hereditary angioedema (HAE) attacks in any body location. This latest authorization brings the number of countries to 28 (in Europe, Asia, North America, South America and Australia) in which Berinert is now licensed.

28 May 2010

NOXXON Pharma closes €33 million Series D round of financing

NOXXON Pharma AG, a company focused on the development of mirror image oligonucleotide therapeutics called Spiegelmers®, announced today the successful closing of a €33 million Series D round of financing. The round was led by new investor, NGN Capital, and joined by existing investors TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, Seventure Partners, VC Fonds Technologie Berlin GmbH, Dow Venture Capital, FCP OP MEDICAL BioHealth-Trends, IBG Beteiligungsgesellschaft Sachsen-Anhalt mbH, the Dieckell Group, and others.

27 May 2010

YM BioSciences initiates enrollment in nimotuzumab trial in brain metastases from NSCLC

YM BioSciences Inc., today announced that the first US patient has been enrolled in its randomized, double-blind trial evaluating nimotuzumab in patients with brain metastases from NSCLC at the Florida Cancer Institute - New Hope. This trial initiation follows recent clearance from the US FDA announced on January 26, 2010 allowing the Company to enroll patients at US clinical sites for two of its international and ongoing randomized, double-blind Phase II trials of nimotuzumab.

27 May 2010

Pfizer plans recruitment halt to EMPHASIS-HF trial

Pfizer Inc. announced that it plans to halt recruitment to the EMPHASIS-HF trial early on the recommendations of the trial's independent Executive Steering Committee (ESC). The recommendations follow a second interim analysis by the independent Data Safety Monitoring Committee (DSMC) of the EMPHASIS-HF trial confirming the study has reached its primary efficacy endpoint early according to the protocol pre-defined stopping rules.

27 May 2010

Shark cartilage extract shows no benefit for patients with advanced non-small cell lung cancer

In the first scientific study of its kind, shark cartilage extract, AE-941 or Neovastat, has shown no benefit as a therapeutic agent when combined with chemotherapy and radiation for patients with advanced non-small cell lung cancer, according to researchers at The University of Texas MD Anderson Cancer Center.

27 May 2010

Cordis announces launch of ExoSeal Vascular Closure Device

Cordis Corporation, a worldwide leader in the development and manufacture of interventional vascular technology, announced the launch of the ExoSeal(TM) Vascular Closure Device. ExoSeal(TM) incorporates a number of new advances in technology and simplicity of design to provide precise and secure extravascular arterial closure. Cordis Corporation received CE-Marking approval for ExoSeal(TM) Vascular Closure Device in May 2010.

27 May 2010

Wireless monitoring system for people with debilitating conditions

A wireless monitoring system for people with debilitating conditions such as Parkinson's disease or chronic obstructive pulmonary disorder could allow healthcare workers to assess a patient's health and the development of their disease without hindering their movements. Details of the system are reported in the International Journal of Biomedical Engineering and Technology.

27 May 2010

Modified measles virus may hold potential for treatment of medulloblastoma

The use of modified measles virus may represent a new treatment for a childhood brain tumor known as medulloblastoma, according to a new study appearing in Neuro-Oncology.

27 May 2010

New study holds promise for patients with LCA

A new study led by Dr. Robert Koenekoop at the Montreal Children's Hospital at the McGill University Health Centre holds promise for certain patients with Leber congenital amaurosis, an inherited retinal degenerative disease that causes significant vision loss from birth. The study, sponsored by Canadian company QLT Inc., is designed to treat patients with LCA due to genetic mutations in either retinal pigment epithelium protein 65 or lecithin:retinol acyltransferase.

27 May 2010

Restanza shows greater efficacy against species of Plasmodium that cause malaria

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced positive results from in vitro and in vivo studies assessing the efficacy of Restanza (cethromycin), its novel oral antibiotic, against the species of Plasmodium that cause malaria.

27 May 2010

Efficacy News and Research

Age of patients makes a difference in comparing endarteroctomy with carotid stenting for stroke-prevention

Relevare Pharmaceuticals to present CNSB015 Phase IIa results at international neuropathic pain congress

Effective infant vaccination against pneumonia needed in sub-Saharan Africa

Nymox Pharmaceutical announces symposium and panel discussion on NX-1207 drug for BPH

CytRx's bafetinib demonstrates significant inhibition of glioblastoma multiforme cell lines in preclinical trial

Biomedical engineering professor receives Transition Career Development Award

Alimera Sciences provides new data from Iluvien Phase 3 FAME clinical trials for DME

PAS announces Cross Marketing agreement with MedLink

OHSU partners with UO, Harvard to expedite research into compounds that may prevent Fanconi anemia

Research finding may offer future alternative to antibiotics

CSL Behring granted authorization to market Berinert for HAE in Italy and Luxembourg

NOXXON Pharma closes €33 million Series D round of financing

YM BioSciences initiates enrollment in nimotuzumab trial in brain metastases from NSCLC

Pfizer plans recruitment halt to EMPHASIS-HF trial

Shark cartilage extract shows no benefit for patients with advanced non-small cell lung cancer

Cordis announces launch of ExoSeal Vascular Closure Device

Wireless monitoring system for people with debilitating conditions

Modified measles virus may hold potential for treatment of medulloblastoma

New study holds promise for patients with LCA

Restanza shows greater efficacy against species of Plasmodium that cause malaria

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News